BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 21, 2005
View Archived Issues
DOR's OrBec For Treating iGVHD Now On NDA Track
Despite missing the primary endpoint in a pivotal trial for orBec to treat intestinal graft-vs.-host disease (iGVHD), DOR BioPharma Inc. intends to file a new drug application before the end of the year. (BioWorld Today)
Read More
Coley's IPO Seeking $115M To Expand Work With TLRs
Read More
Arguments Heard In Supreme Court On Early Research IP
Read More
Molecular Insight Raises $28M In Series C For Imaging Product
Read More
Corgentech Cuts Staff To Slow Spending After E2F Decoy Miss
Read More
With RA Product In Phase II, Merrimack Brings In $28.3M
Read More
Other News To Note
Read More